Cowen & Co. Initiates Coverage On EXACT Sciences Corporation(EXAS). In a research note issued to the investors, the brokerage major Announces the price-target to $30 per share. The shares have been rated Outperform. The rating by the stock financial advisor at Cowen & Co. was issued on Mar 27, 2017 in a research report to their Investors and Clients.
In a different note, On Feb 22, 2017, Roth Capital said it Upgrades its rating on EXACT Sciences Corporation. The shares have been rated ‘Buy’ by the firm. On Feb 22, 2017, Roth Capital said it Upgrades its rating on EXACT Sciences Corporation. The shares have been rated ‘Buy’ by the firm.
EXACT Sciences Corporation (EXAS) made into the market gainers list on Fridays trading session with the shares advancing 2.88% or 0.59 points. Due to strong positive momentum, the stock ended at $21.08, which is also near the day’s high of $21.33. The stock began the session at $20.44 and the volume stood at 23,10,510 shares. The 52-week high of the shares is $24.5 and the 52 week low is $5.36. The company has a current market capitalization of $2,332 M and it has 11,06,03,808 shares in outstanding.
EXACT Sciences Corporation(EXAS) last announced its earnings results on Feb 21, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $35.241M. Analysts had an estimated revenue of $32.530M. Earnings per share were $-0.34. Analysts had estimated an EPS of $-0.4.
Several Insider Transactions has been reported to the SEC. On Mar 14, 2017, Graham Peter Lidgard (Chief Science Officer) sold 2,945 shares at $21.16 per share price.Also, On Mar 14, 2017, D Scott Coward (SVP and General Counsel) sold 1,983 shares at $21.16 per share price.On Mar 14, 2017, Kevin T Conroy (President and CEO) sold 12,059 shares at $21.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.